Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors

NCT04696055 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04696055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04696055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2021
Completion date
April 23, 2024
Enrollment
95 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma